

ILLUSTRATED REVIEW

Illustrated State-of-the-Art Capsules of the ISTH 2023 Congress

Susan R. Kahn MD, MSc¹  | Donald M. Arnold MD, MSc²  |
Caterina Casari PhD³   | Karl C. Desch MD⁴  | Katrien M. J. Devreese⁵ |
Emmanuel J. Favaloro⁶ | Florian Gaertner MD, PhD⁷ | Samantha C. Gouw⁸ |
Paolo Gresele⁹ | Arjan W. Griffioen¹⁰  | Lukas Heger^{11,12,13}  |
R. Manjunatha Kini PhD¹⁴ | Shrey Kohli¹⁵  | Avi Leader MD¹⁶  |
Ton Lisman PhD¹⁷ | Marie Lordkipanidzé BPharm, MSc, PhD, FOPQ¹⁸  |
Eric Mullins MD^{19,20}  | Helen Chioma Okoye MBBS, MSc, FMCPPath, FWACP²¹  |
Rachel P. Rosovsky²²  | Isabelle I. Salles-Crawley PhD²³  |
Rita Selby MBBS, FRCPC, MSc²⁴  | Michelle Sholzberg MDCM, MSc, FRCPC²⁵  |
David Stegner PhD²⁶  | Francesco Violi MD²⁷ | Angela C. Weyand MD²⁸  |
Suzan Williams BSc, MSc, MD²⁹ | Ze Zheng MBBS, PhD^{30,31} 

¹Medicine, Sir Mortimer B Davis Jewish General Hospital, McGill University, 3755 Cote Ste Catherine, Montreal, Quebec

²Department of Medicine, McMaster University, Hamilton, ON, Canada

³Université Paris-Saclay, INSERM, Hémostase inflammation thrombose HITH U1176, 94276, Le Kremlin-Bicêtre, France

⁴Cell and Molecular Biology Program, University of Michigan, Ann Arbor, USA

⁵Coagulation Laboratory, Department of Laboratory Medicine, Ghent University Hospital, Department of Diagnostic Sciences, Ghent University, Ghent, Belgium

⁶Haematology, Sydney Centres for Thrombosis and Haemostasis, Institute of Clinical Pathology and Medical Research (ICPMR), NSW Health Pathology, Westmead Hospital, Westmead, NSW Australia

⁷Technische Universität München (TUM), Ismaninger Straße 22, München, Bayern 81675, Germany

⁸Amsterdam UMC location University of Amsterdam, Department of Pediatric Hematology, Meibergdreef 9, Amsterdam, The Netherlands

⁹University of Perugia, Department of Medicine and Surgery, Head Section of Internal and Cardiovascular Medicine

¹⁰Angiogenesis Laboratory, Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands

¹¹Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA; Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115, USA; Department of Cardiology and Angiology, University Hospital Freiburg Bad Krozingen, 79106 Freiburg, Germany

¹²Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115, USA

¹³Department of Cardiology and Angiology, University Hospital Freiburg Bad Krozingen, 79106 Freiburg, Germany

¹⁴National University of Singapore, Singapore

¹⁵Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, Universitätsklinikum Leipzig, Leipzig University, 04103 Leipzig, Germany

¹⁶Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

¹⁷Surgical Research Laboratory and Section of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands

¹⁸Faculty of pharmacy, University of Montreal

¹⁹Division of Hematology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA

²⁰University of Cincinnati - College of Medicine, Cincinnati, OH, USA

²¹College of Medicine, University of Nigeria, Ituku Ozalla campus, Enugu Nigeria

²²Massachusetts General Hospital

²³St George's University of London

²⁴Departments of Laboratory Medicine & Pathobiology and Department of Medicine, University of Toronto

²⁵St. Michael's Hospital, University of Toronto

²⁶Julius-Maximilians-Universität Würzburg

²⁷Department of Clinical, Internal Medicine, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy

²⁸Department of Pediatrics, University of Michigan Medical School

²⁹Hospital for Sick Children, University of Toronto

³⁰Medical College of Wisconsin, Milwaukee, Wisconsin 53226, USA

³¹Versiti Blood Research Institute, Milwaukee, Wisconsin 53226, USA

Abstract







This year's Congress of the International Society of Thrombosis and Haemostasis (ISTH) took place in person in Montréal, Canada, from June 24-28, 2023. The conference, held annually, highlighted cutting-edge advances in basic, translational, population and clinical sciences relevant to the Society. As for all ISTH congresses, we offered a special, congress-specific scientific theme; this year, the special theme was immunothrombosis. Certainly, over the last few years, COVID-19 infection and its related thrombotic and other complications have renewed interest in the concepts of thromboinflammation and immunothrombosis; namely, the relationship between inflammation, infection and clotting. Other main scientific themes of the Congress included Arterial Thromboembolism, Coagulation and Natural Anticoagulants, Diagnostics and Omics, Fibrinolysis and Proteolysis, Hemophilia and Rare Bleeding Disorders, Hemostatic System in Cancer, Inflammation and Immunity, Pediatrics, Platelet Disorders, von Willebrand Disease and Thrombotic Microangiopathies, Platelets and Megakaryocytes, Vascular Biology, Venous Thromboembolism and Women's Health. Among other sessions, the program included 28 State-of-the-Art (SOA) sessions with a total of 84 talks given by internationally recognized leaders in the field. SOA speakers were invited to prepare brief illustrated reviews of their talks that were peer reviewed and are included in this article. These illustrated capsules highlight the major scientific advances with potential to impact clinical practice. Readers are invited to take advantage of the excellent educational resource provided by these illustrated capsules. They are also encouraged to use the image in social media to draw attention to the high quality and impact of the science presented at the Congress.

CONTENTS

Donald M Arnold, MD MSc	Immune Attack on Platelets
Caterina Casari, PhD	Novel therapeutics for VWD
Karl C Desch, MD	Complex Trait Genetics in Thrombosis and Haemostasis
Katrien M.J. Devreese	Antiphospholipid syndrome: a challenging diagnosis
Emmanuel J. Favaloro	Testing for the Lupus Anticoagulant (LA) Over the Last Decade – Are We There Yet?
Florian Gaertner, MD, PhD	Single Platelet Morpho-Dynamics Uncovered by Multicolor Reporter Mouse Strains in Vitro and in Vivo
Samantha C. Gouw	Approach to PUPs in 2023
Paolo Gresele	Immune Attack on Platelets in ITP: The Role of Megakaryocyte Impairment
Arjan W. Griffioen	Anti-angiogenic agents as immune modulators
Lukas Heger	PAD4 Inhibition in Immunothrombosis
R. Manjunatha Kini, PhD	Variegain, a Potent Direct Thrombin Inhibitor From Tick Saliva
Shrey Kohli	Thrombo-inflammatory Mechanisms at the Fetal-Maternal Interface
Avi Leader, MD	Cancer and Arterial Thrombosis: Therapeutic Options
Ton Lisman, PhD	Fibrinolysis in patients with liver disease
Marie Lordkipanidzé, BPharm, MSc, PhD, FOPQ	Platelets and Neurotrophins
Eric Mullins, MD	Thrombosis Risk associated with Transgender Care
Helen Chioma Okoye; MBBS, MSc, FMCPATH, FWACP	Insights and Challenges to Accessible Care for Women With Thrombosis and Hemostasis Disorders
Rachel P. Rosovsky	Pulmonary Embolism Response Teams: Purpose, Evidence for Efficacy, and Future Directions
Isabelle I. Salles-Crawley, PhD	Platelet receptors in immunothrombosis
Rita Selby, MBBS, FRCPC, MSc	D-dimer diagnostics: Can I use any D-dimer assay? Bridging the knowledge-to-action gap
Michelle Sholzberg MDCM, MSc., FRCPC	Barriers and Myths to Use of Tranexamic Acid for Vaginal Bleeding
David Stegner, PhD	Thrombo-Neuroinflammatory Disease
Francesco Violi, MD	Gut microbiota and cardiovascular risk
Angela C. Weyand, MD	Von Willebrand Disease Laboratory Diagnosis – Does My Patient Have VWD?
Suzan Williams, BSc, MSc, MD	Hemoglobinopathy and Thrombosis
Ze Zheng, MBBS, PhD	Fibrinolysis in Obesity and Dyslipidemia

Immune attack on platelets


Donald M. Arnold, MD, MSc

Immune attack on platelets		
Reaction	Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT)	Vaccine-Associated Immune Thrombocytopenia (VA-ITP)
Described With	Adenoviral vector vaccines (e.g. Johnson and Johnson, AstraZeneca) 	Any vaccine (especially Covid-19 and measles, mumps, and rubella vaccines) 
Pathophysiology	<p>The vaccine stimulates anti-PF4 antibody production</p>  <p>The anti-PF4 antibodies bind to circulating PF4 (which originate from inside platelets) and membrane-bound PF4 on the platelet surface, causing Fc-mediated platelet activation</p>	<p>The vaccine stimulates anti-GPIIb/IIIa and anti-GPIb/IX antibody production</p>  <p>The anti-GPIIb/IIIa and anti-GPIb/IX antibodies bind to GPIIb/IIIa and GPIb/IX on the platelet surface, and the antibody-tagged platelets are destroyed in the spleen</p>
Clinical Findings	<p>The platelet activation leads to thrombocytopenia and thrombosis</p> 	<p>The platelet destruction leads to thrombocytopenia and bleeding</p> 
Incidence Estimate	~1:100,000 with adenoviral vector vaccines	~1:100,000 (or more common) with any vaccine
Management	Non-heparin anticoagulant, IVIG, +/- immune suppressant medications	Corticosteroids, IVIG, thrombopoietin receptor agonists, +/- immune suppressant medications

For references, see Kelton et al. [1] and Arnold and Kelton [2]

Novel therapeutics for VWD

Caterina Casari, PhD



Von Willebrand disease (VWD) is associated with heterogeneous, difficult to quantify bleedings but limited treatment options are currently available. While clinicians generally appreciate that available treatments are quite effective in controlling the bleeding episodes, VWD patients perceive the burden of invasive, mostly on-demand treatments [3]. New therapeutic strategies are under investigation for patients with similar phenotypes, with the hope of better fulfilling their needs. BT200 (rondoraptivon pegol) is a pegylated aptamer inhibiting VWF/GPIIb α interaction that increases VWF/FVIII levels and, in thrombocytopenic patients, also rises platelet counts [4]. KB-V13A12 is a bispecific nanobody simultaneously binding albumin and VWF, which corrects haemostasis in a VWD-type 1 mouse model. Emicizumab, has been efficiently used in VWD-type 3 patients [5] and mice, but has no beneficial effects in a VWD-type 2A mouse model. Synthetic platelet nanoparticles that collaborate with endogenous platelets, have been successfully tested in VWD-type 3 and -2B mouse models.

TXA, tranexamic acid; QoL, quality-of-life; HMB, heavy menstrual bleedings; GI, gastrointestinal; NHPs, non-human primates.

Complex trait genetics in thrombosis and haemostasis


Karl C. Desch, MD

Complex trait genetics in thrombosis and haemostasis

Human Variants


Common Variants

1. Generated by SNP-Chip and Imputation
2. Low effect size
3. Primary use: Genome-wide Association Studies



Rare Variants

1. Generated by Next Generation Sequencing
2. Potentially high effect size
3. Primary use: Rare variant, Collapsing analyses



Human Variant Applications


1. Mendelian Randomization
2. Colocalization studies
3. Polygenic Risk Scores

Disease	N _{control}	N _{dise}
Coronary Artery Disease	386,581	22,333
Myocardial Infarction	391,853	17,041
Peripheral Artery Disease	403,178	5,716
Atrial Fibrillation	389,031	19,863
Stroke	398,090	10,804
Venous Thromboembolism	392,652	15,365
Intracerebral Hemorrhage	407,816	1,078
Hypertension	267,082	141,812
Aortic Valve Stenosis	406,359	2,535
Pulmonary Embolism	404,322	4,572
Subarachnoid Hemorrhage	407,717	1,177
Heart Failure	400,799	8,005
Ischemic Stroke	403,847	5,047

Synthetic Variants


Deep Mutational Scan

Probing missense variant effects on variant protein abundance and function




CRISPR Screens

Probing gene networks altering protein abundance or cell trafficking



Proximity Labeling


Probing protein-protein interactions



Antiphospholipid syndrome: a challenging diagnosis

Katrien M.J. Devreese

Antiphospholipid syndrome: a challenging diagnosis



Antiphospholipid syndrome (APS) is an autoimmune disease characterized by thrombosis and/or pregnancy morbidity, in patients persistently positive for antiphospholipid antibodies (aPL). Classification criteria restrict the aPL to lupus anticoagulant (LAC), anti-cardiolipin (aCL) and anti-beta2-glycoprotein I (β 2GPI) antibodies (a β 2GPI) IgG or IgM. However, in clinical practice patients may present with a variety of clinical symptoms, not fulfilling the classification criteria for overt APS, and other aPL may help to diagnose APS.


LAC testing remains a complicated procedure using coagulation assays with many pitfalls and interferences. Assays for aCL and a β 2GPI show inter-assay differences. These methodological issues make the laboratory diagnosis of APS challenging, and other aPL tests (antibodies against the domain I of β 2GPI and antiphosphatidylserine-prothrombin (aPS/PT) antibodies, as well as antibody profiles and semi-quantitative reporting of titers may help in the laboratory diagnosis of APS.

On both diagnostic sides, clinical and laboratory, APS is heterogeneous and challenging to diagnose.

For references, see Devreese et al. [6,8]; Barbhaiya et al. [7]

Testing for the lupus anticoagulant (la) over the last decade – are we there yet?


Emmanuel J. Favaloro



Single platelet morpho-dynamics uncovered by multicolor reporter mouse strains in vitro and in vivo

Florian Gaertner, MD, PhD

Single platelet morpho-dynamics uncovered by multicolor reporter mouse strains in vitro and in vivo




For references, see Gaertner et al. [9]; Nicolai et al. [10,11]

Approach to PUPs in 2023

Samantha C. Gouw


Approach to previously untreated patients with severe hemophilia A in 2023



The optimal treatment approach for individual PUPs is not fully known (optimal age to start, FVIII tolerance, long term joint health)

Immune attack on platelets in ITP: the role of megakaryocyte impairment

Prof. Paolo Gresele



Auto-Abs: auto-antibodies; **BM:** bone marrow; **DMS:** demarcation membrane system; **HSC:** hematopoietic stem cell; **MK:** megakaryocyte; **SDF-1α:** stromal cell-derived factor-1α.

Immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized by accelerated platelet turnover due to circulating auto-antibodies (Abs) against platelet and megakaryocyte (MK) surface glycoproteins, such as $\alpha_{IIb}\beta_3$ -GPIIb/IIIa, $\alpha_2\beta_1$ -GPIa/IIa, GPIb/IX/V, GPIV, GPVI and $\alpha_v\beta_3$.

Immunological cells reside and produce Abs in the bone marrow (BM) [12]. Platelet auto-antibodies were detected in the BM of ITP patients [13].


Besides increased clearance of circulating opsonized platelets, platelet auto-antibodies lead to the impairment of many steps of megakaryo/thrombopoiesis, such as MK differentiation and maturation, MK migration from the osteoblastic to the vascular niche, MK adhesion to extracellular matrix proteins, and proplatelet formation, resulting in impaired and ectopic platelet production in the BM and diminished platelet release in the blood stream.

The figure was created with [BioRender.com](https://www.biorender.com)

Anti-angiogenic agents as immune modulators

Arjan W. Griffioen


Anti-angiogenic agents as immune modulators



Ongoing angiogenesis, induced by vascular endothelial- and fibroblast growth factors, protects a tumor against leukocyte infiltration through the suppression of endothelial cell (EC) adhesion molecule expression. The main adhesion molecule involved in leukocyte infiltration is intercellular adhesion molecule-1 (ICAM-1). This molecule is both sufficient, as well as required for leukocyte extravasation and is heavily suppressed in the tumor vasculature [14]. Other adhesion molecules such as vascular cell adhesion molecules and E-selectin are also involved. Non-adhesive endothelium, which is the result of tumor endothelial cell anergy, provides the tumor with immune silent conditions, a trait that has been hijacked from embryo development. Inhibition of angiogenesis, by drugs such as bevacizumab, axitinib and Lenvatinib, overcomes endothelial anergy and restores the suppressed expression of ICAMs, VCAMs and selectins in the endothelium and supports anti-tumor immunity [15]. It is becoming evident that the recent FDA approvals for combination therapies of anti-angiogenic agents with immune checkpoint inhibitors [16] are based on the phenomenon of overcoming endothelial cell anergy.

PAD4 inhibition in immunothrombosis


Lukas Heger



Variegin, a potent direct thrombin inhibitor from tick saliva


R. Manjunatha Kini, PhD

Variegin, a potent direct thrombin inhibitor from tick saliva



Thrombo-inflammatory mechanisms at the fetal-maternal interface


Shrey Kohli



Platelet-mediated inflammatory mechanisms within the placenta contribute to thrombo-inflammatory gestational vascular complications (TIGVCs) such as preeclampsia (PE) and anti-phospholipid (aPL) syndrome. This impairs fetal-maternal health during pregnancy, and promote long-term disease priming mechanisms in the mother and the offspring. Pro-coagulant extracellular vesicles (pcEVs) promote platelet activation thereby releasing DAMPs such as ATP which in turn activate the NLRP3 inflammasome and placental sterile inflammation via purinergic receptor (P2X) signaling [17]. This is associated with reduced placental thrombomodulin (TM) expression. TM deficiency results in a tissue-factor (TF) dependent and platelet-mediated embryonic loss in mice. Endothelial protein-C receptor (EPCR) deficiency causes mid-gestational embryonic death via integrin and PAR mediated platelet activation and neutrophil infiltration [18]. On the other hand, EPCR expressing trophoblast promotes aPL antibody mediated signaling and TNF- α release promoting systemic inflammation. Beyond the role of EPCR, aPL antibodies promote complement (C3 & C5) and TF mediated neutrophil infiltration, trophoblast injury and fetal loss [19].

Cancer and arterial thrombosis: therapeutic options

Avi Leader, MD



Acute coronary syndrome (less PCI and less use of potent P2Y12 inhibitors) and atrial fibrillation (~50% don't receive anticoagulation despite an indication) are under-treated in cancer patients. These patients present unique treatment challenges [20,21,22], have an increased bleeding risk, and require management tailored to the cancer setting.

* Address modifiable cardiovascular risk factors

** ESUS defined as a non-lacunar stroke, without a stenotic arterial culprit lesion, and without a known high-risk cardioembolic source


Abbreviations:

ACS, acute coronary syndrome; ADT, androgen deprivation therapy; CAD, coronary artery disease; DAPT, dual antiplatelet therapy; ESUS, embolic stroke of undetermined source; HITS, high-intensity transient signals; ICI, immune checkpoint inhibitor; LMWH, low molecular weight heparin; NBTE, non-bacterial thrombotic endocarditis; NSTEMI-ACS, non-ST elevation acute coronary syndrome; PCI, percutaneous coronary intervention; PFO, patent foramen ovale; Rx, treatment; STEMI, ST elevation myocardial infarction; TCD, transcranial doppler; TEE, transesophageal echocardiography; VEGFi, vascular endothelial growth factor inhibitor; VTE, venous thromboembolism

Fibrinolysis in patients with liver disease

Ton Lisman, PhD


Fibrinolysis in patients with liver disease



For references, see von Meijenfeldt [23]; Driever [24]

Platelets and neurotrophins

Marie Lordkipanidzé, BPharm, MSc, PhD, FOPQ




The better characterized neurotrophin in platelet biology is the Brain-Derived Neurotrophic Factor (BDNF), which induces platelet aggregation through binding of its truncated receptor Tropomyosin-related Kinase B (TrkB) on the platelet surface. The regulation of BDNF in the bloodstream is dependent on alpha2-macroglobulin, limiting platelet activation to the site of vascular injury. While it is known that platelets are the main reservoir of BDNF in circulation, the origin of the platelet pool of BDNF remains debated. It appears to be partly inherited from megakaryocytes, and possibly also endocytosed from circulation. Surprisingly, in addition to packaging BDNF into platelets, megakaryocytes release BDNF during megakaryopoiesis, the role of which both in the bone marrow and in circulation remains to be established. Also present on the platelet surface are the other neurotrophin receptors (TrkA, TrkC & p75^{NTR}). However, their role and signaling mechanisms remain largely unknown.

For references, see Boukhatem et al. [25]; Fleury et al. [26]; Chacón-Fernández et al. [27]


Thrombosis risk associated with transgender care

Eric Mullins, MD



Insights and challenges to accessible care for women with thrombosis and hemostasis disorders

Helen Chioma Okoye; MBBS, MSc, FMCPATH, FWACP




SES – socioeconomic status; RAM – risk assessment model; CBC – complete blood count; APTT – activated partial thromboplastin time test; PT – prothrombin time test

For references, see Arya et al. [28]; Okoye et al. [29]; Murray et al. [30]


Pulmonary embolism response teams: purpose, evidence for efficacy, and future directions

Rachel P. Rosovsky



Platelet receptors in immunothrombosis


Isabelle I. Salles-Crawley, PhD



1. Venous valve pockets are prone to thrombosis where disturbed flow/stasis creates a pro-thrombotic milieu where hypercoagulability of the blood, hypoxia and endothelial dysfunction trigger thrombus formation which further precipitate this vicious circle.
2. Procoagulant VWF is released from endothelial cells, and under disturbed flow conditions can become unravelled, exposing its A1 domain enabling platelet binding via GPIb α .
3. The VWF-GPIb α interaction under flow induces mechanosensitive signalling leading to Ca²⁺ release from platelet intracellular stores and activation of $\alpha_{IIb}\beta_3$.
4. Neutrophils via SLC44A2 can bind activated $\alpha_{IIb}\beta_3$ on primed platelets and undergo NET formation that is dependent upon shear forces.
5. Activated neutrophils can directly activate platelets through release of granules (e.g. LL-37, neutrophil elastase [NE], cathepsin G [CG], myeloperoxidase [MPO]) or indirectly by generating thrombin via NETs [activation of FXIIa and inhibition of TFPI]
6. Activated platelets can bind to monocytes and neutrophils and further activate them by releasing granule content (e.g. P-selectin, HMGB1, CCL5, CXCL4, CXCL5, serotonin). Monocytes and neutrophils are recruited to the endothelium via PSGL-1 binding to endothelial P-selectin. NETs promote thrombus development and stability which ultimately block the valve and upstream vein causing deep vein thrombosis.

D-dimer diagnostics: can i use any D-dimer assay? bridging the knowledge-to-action gap


Rita Selby, MBBS, FRCPC, MSc



VTE - venous thromboembolism

Barriers and myths to use of tranexamic acid for vaginal bleeding

Michelle Sholzberg MDCM, MSc., FRCPC




Heavy vaginal bleeding is the most common symptom experienced by women with bleeding disorders [31]. Tranexamic acid (TXA) is an antifibrinolytic agent that is highly effective in the treatment of heavy vaginal bleeding. Despite its known benefits, there are pervasive myths, individual- and structural-level barriers that preclude its use, interfere with effective patient care and propagate health inequity in women's health. [31,32,33].

Thrombo-neuroinflammatory disease

David Stegner, PhD

Thrombo-Neuroinflammatory Disease




Interactions between platelets, endothelial cells and immune cells contribute to cerebral damage in the context of ischemic stroke and cerebral venous thrombosis (CVT) [34-36]. Following ischemic stroke, platelets become activated at the (post-)ischemic endothelium and procoagulant (promoting plasmatic coagulation and fibrin formation) and secrete their granule content. This contributes to blood brain barrier breakdown and promotes the formation of neutrophil extracellular traps (NETs). Moreover, platelet receptors are shed and soluble CD84 recruits T cells that further aggravate infarct progression. Notably, following recanalization, cerebral thrombosis is no major driver of infarct progression anymore. Instead, proper platelet aggregation is critical to prevent intracerebral hemorrhage in the post-ischemic phase.

In the context of CVT, the situation is different: Here, inflammation triggers overshooting platelet activation resulting in occlusive thrombus formation leading to detrimental CVT. Still, the underlying mechanisms are poorly understood, but platelet (hem)ITAM receptors and $\alpha\text{IIb}\beta\text{3}$ seem to be crucial.

Gut microbiota and cardiovascular risk

Francesco Violi, MD




Gut dysbiosis may enhance gut permeability to elicit translocation of lipopolysaccharide (LPS) into portal and eventually systemic circulation. Gut as well as liver cells possess an enzymatic armamentarium to catabolize or blunt the toxic effect of LPS. Thus, intestinal cells express the intestinal alkaline phosphatase, that catabolizes LPS, and synthesizes HDL3, that prevents LPS interaction with its receptor toll-like receptor 4 (TLR4); similarly, livers cells express an alkaline phosphatase and hydrolases to catabolize LPS. In case of exaggerated LPS translocation into portal circulation, LPS localizes into liver cells and eventually arterial wall, where it can induce an inflammatory status by interacting with TLR4, leading to non-alcoholic fatty liver disease or favoring atherosclerotic and thrombotic process respectively [37].

Von willebrand disease laboratory diagnosis – does my patient have VWD?

Angela C. Weyand, MD


Von willebrand disease laboratory diagnosis – does my patient have VWD?



Hemoglobinopathy and thrombosis

Suzan Williams, BSc, MSc, MD


Hemoglobinopathy & Thrombosis



The activation of the coagulation system in hemoglobinopathy is multifactorial. Hemolysis a triggering factor for thrombosis in both sickle cell disease and thalassemia. Endothelial activation and injury, increased platelet activation, platelet aggregation, vasoconstriction from a dysregulated NO pathway all contribute to thrombotic risk. The increased recognition of thrombotic events in patients with hemoglobinopathy warrant future studies to optimize prevention and treatment.

Fibrinolysis in obesity and dyslipidemia

Ze Zheng, MBBS, PhD



Obesity increases risks for arterial, venous, and microvascular thrombosis. Hepatocytes synthesize both tissue plasminogen activator (tPA), the serine protease initiating fibrinolysis and the serpin plasminogen activator inhibitor, PAI1 [38,39]. A balance between tPA and PAI1 in plasma is important for breaking down fibrin clot without compromising clotting. The hepatocyte-derived tPA contributes to basal blood tPA concentration, and works in concert with tPA released from endothelium upon vascular injury, thereby initiating fibrinolysis [39]. Lipid-overloaded hepatocytes have reduced transcription co-repressor Rev-Erba, leading to increased PAI-1, which then stimulates tPA synthesis via a PAI-1-LRP1-PKA-p-CREB1 pathway [40]. This PAI-1-stimulating tPA production mechanism functions as a compensatory pathway to compete with the large increase of PAI-1. However, the small induction of tPA synthesis is limited by its transcription repressor DACH1, which is induced in obese livers. In hepatocytes, where lipids are loaded and incorporated into lipoproteins, this PAI-1-tPA regulatory network influences the degree of impaired fibrinolysis in obesity [40].

TWITTER

Susan R. Kahn  @SusanRKahn1
 Donald M. Arnold  @arnolddma1
 Caterina Casari  @caterinacasari;  @InsermU1176
 Karl C. Desch  @Loochando
 Arjan W. Griffioen  @AngiogenesisA
 Lukas Heger  @LukasHegerMD
 Shrey Kohli  @kohli_shrey
 Avi Leader  @LeaderAvi
 Marie Lordkipanidzé  @Mtl_PlateletLab
 Eric Mullins  @ericsmullins
 Helen Chioma Okoye  @doctorhelenc
 Rachel P. Rosovsky  @RosovskyRachel
 Isabelle I. Salles-Crawley  @Salles_Crawley
 Rita Selby  @Ritaselby1
 Michelle Sholzberg  @SHOLZBERG
 David Stegner  @StegnerLab
 Angela C. Weyand  @acweyand
 Ze Zheng  @DrZeZheng

REFERENCES

- [1] Kelton JG, Arnold DM, Nazy I. Lessons from vaccine-induced immune thrombotic thrombocytopenia. *Nat Rev Immunol.* 2021 Dec;21(12):753–5.
- [2] Arnold DM, Kelton JG. Current options for the treatment of idiopathic thrombocytopenic purpura. *Semin Hematol.* 2007 Oct;44(4 Suppl 5):S12–23.
- [3] Denis CV, Susen S, Lenting PJ. von Willebrand disease: what does the future hold? *Blood.* 2021;137:2299–306.
- [4] Kovacevic KD, Grafeneder J, Schörghofer C, Gelbenegger G, Gager G, Firbas C, Quehenberger P, Jilma-Stohlawetz P, Bileck A, Zhu S, Gilbert JC, Beliveau M, Jilma B, Derhaschnig U. The von Willebrand factor A-1 domain binding aptamer BT200 elevates plasma levels of von Willebrand factor and factor VIII: a first-in-human trial. *Haematol.* 2021;107:2121–32.
- [5] Weyand AC, Flood VH, Shavit JA, Pipe SW. Efficacy of emicizumab in a pediatric patient with type 3 von Willebrand disease and alloantibodies. *Blood Adv.* 2019;3:2748–50.
- [6] Devreese KMJ, Ortel TL, Pengo V, de Laat B. Subcommittee on Lupus Anticoagulant/Antiphospholipid A. Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH. *J Thromb Haemost.* 2018;16(4):809–13.
- [7] Barbhaya M, Zuily S, Ahmadzadeh Y, Amigo MC, Avcin T, Bertolaccini ML, Branch DW, de Jesus G, Devreese KMJ, Frances C, Garcia D, Guillemin F, Levine SR, Levy RA, Lockshin MD, Ortel TL, Seshan SV, Tektonidou M, Wahl D, Willis R, et al. Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria. *Arthritis Care Res.* 2021;73:1490–501. <https://doi.org/10.1002/acr.24520>
- [8] Devreese KMJ, de Groot PG, de Laat B, Erkan D, Favaloro EJ, Mackie I, Martinuzzo M, Ortel TL, Pengo V, Rand JH, Tripodi A, Wahl D, Cohen H. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: Update of the guidelines for lupus anticoagulant detection and interpretation. *J Thromb Haemost.* 2020;18:2828–39. <https://doi.org/10.1111/jth.15047>
- [9] Gaertner F, et al. Migrating Platelets Are Mechano-scavengers that Collect and Bundle Bacteria. *Cell.* 2017;171:1368–1382 e1323. <https://dx.doi.org/10.1016/j.cell.2017.11.001>
- [10] Nicolai L, et al. Vascular surveillance by haptotactic blood platelets in inflammation and infection. *Nat Commun.* 2020;11:5778. <https://dx.doi.org/10.1038/s41467-020-19515-0>
- [11] Nicolai L, et al. Single platelet and megakaryocyte morpho-dynamics uncovered by multicolor reporter mouse strains *in vitro* and *in vivo*. *Haematologica.* <https://dx.doi.org/10.3324/haematol.2021.278896>
- [12] Manz RA, Thiel A, Radbruch A. Lifetime of plasma cells in the bone marrow. *Nature.* 1997;388:133–4.
- [13] Shrestha S, Nazy I, Smith JW, Kelton JG, Arnold DM. Platelet autoantibodies in the bone marrow of patients with immune thrombocytopenia. *Blood Advances.* 2020;4:2962–6.
- [14] Griffioen AW, Damen CA, Martinotti S, Blijham GH, Groenewegen G. Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors. *Cancer Res.* 1996;56(5):1111–7.
- [15] Nowak-Sliwinska P, van Beijnum JR, Griffioen CJ, Huinen ZR, Sopesens NG, Schulz R, Jenkins SV, Dings RPM, Groenendijk FH, Huijbers EJM, et al. Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell energy. *Angiogenesis.* 2022.
- [16] Huinen Z, Huijbers EJM, Van Beijnum JR, Nowak-Sliwinska P, Griffioen AW. Anti-angiogenic agents - overcoming tumor endothelial cell energy and improving immunotherapy outcomes. *Nat Rev Clin Oncol.* 2021;18(8):527–40.
- [17] Kohli S, et al. Maternal extracellular vesicles and platelets promote preclampsia through inflammasome activation in embryonic trophoblast. *Blood.* 2016.
- [18] Castillo MM, et al. The endothelial protein C receptor plays an essential role in the maintenance of pregnancy. *Sci Adv.* 2020;6(45).
- [19] Muller-Calleja N, et al. Lipid presentation by the protein C receptor links coagulation with autoimmunity. *Science.* 2021;(6534):371.
- [20] Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). *Eur Heart J.* 2022;43(41):4229–361. <https://doi.org/10.1093/eurheartj/ehac244>
- [21] Falanga A, Leader A, Ambaglio C, et al. EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer. *Hemasphere.* 2022;6(8):e750. <https://doi.org/10.1097/HS9.0000000000000750>. Published 2022 Jul 13.
- [22] Beavers CJ, Rodgers JE, Bagnola AJ, et al. Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association. *Circulation.* 2022;145(15):e811–38. <https://doi.org/10.1161/CIR.0000000000001056>
- [23] von Meijenfeldt FA, Lisman T. Fibrinolysis in Patients with Liver Disease. *Semin Thromb Hemost.* 2021 Jul;47(5):601–9.
- [24] Driever EG, Lisman T. Fibrin clot properties and thrombus composition in cirrhosis. *Res Pract Thromb Haemost.* 2023 Jan 20;7(1):100055.
- [25] Boukhatem I, Fleury S, Welman M, Le Blanc J, Thys C, Freson K, Best MG, Würdinger T, Allen BG, Lordkipanidzé M. The brain-derived neurotrophic factor prompts platelet aggregation and secretion. *Blood Adv.* 2021;5(18):3568–80.
- [26] Fleury S, Boukhatem I, Le Blanc J, Welman M, Lordkipanidzé M. Tissue-Specificity of Antibodies Raised Against TrkB and p75NTR Receptors; Implications for Platelets as Models of Neurodegenerative Diseases. *Front Immunol.* 2021;12:606861.
- [27] Chacón-Fernández P, Säuberli K, Colzani M, Moreau T, Ghevaert C, Barde YA. Brain-derived Neurotrophic Factor in Megakaryocytes. *J Biol Chem.* 2016;291(19):9872–81.
- [28] Arya S, Wilton P, Page D, Boma-Fischer L, Floros G, Dalnty KN, et al. Healthcare provider perspectives on inequities in access to care for patients with inherited bleeding disorders. *PLoS ONE.* 2020;15(2):e0229099.

- [29] Okoye HC, Korubo KI, Nwogoh B, Efobi CC, Ugwu NI, Madu AJ. Challenges in the management of bleeding disorders in Nigeria. *Nigerian Journal of Clinical Practice*. 2018;21:468–72.
- [30] Murray S, McLintock C, Lazure P, Peniuta M, Schulman S, Rezende SM, et al. *Res Pract Thromb Haemost*. 2019;3:626–38.
- [31] Relke N, Chornenki NL, Sholzberg M. Tranexamic acid evidence and controversies: an illustrated review. *Research and Practice in Thrombosis and Haemostasis*. 2021 Jul;5(5):e12546.
- [32] Lee SG, Fralick J, Wallis CJ, Boctor M, Sholzberg M, Fralick M. Systematic review of hematuria and acute renal failure with tranexamic acid. *European Journal of Haematology*. 2022 Jun;108(6):510–7.
- [33] Chornenki NL, Um KJ, Mendoza PA, Samienezhad A, Swarup V, Chai-Adisaksopha C, Siegal DM. Risk of venous and arterial thrombosis in non-surgical patients receiving systemic tranexamic acid: A systematic review and meta-analysis. *Thrombosis research*. 2019 Jul 1;179:81–6.
- [34] Stoll G, Nieswandt B. Thrombo-inflammation in acute ischaemic stroke - implications for treatment. *Nat Rev Neurol*. 2019;15:473–81.
- [35] Schuhmann MK, Stoll G, Bieber M, Vogtle T, Hofmann S, Klaus V, Kraft P, Seyhan M, Kollikowski AM, Papp L, Heuschmann PU, Pham M, Nieswandt B, Stegner D. CD84 Links T Cell and Platelet Activity in Cerebral Thrombo-Inflammation in Acute Stroke. *Circ Res*. 2020;127:1023–35.
- [36] Stegner D, Göb V, Krenzlín V, Beck S, Hemmen K, Schuhmann MK, Schörg BF, Hackenbroch C, May F, Burkard P, Pinnecker J, Zerneck A, Rosenberger P, Greinacher A, Pichler BJ, Heinze KG, Stoll G, Nieswandt B. Foudroyant cerebral venous (sinus) thrombosis triggered through CLEC-2 and GPIIb/IIIa dependent platelet activation. *Nat Cardiovasc Res*. 2022;1:132–41.
- [37] Violi F, Cammisotto V, Bartimoccia S, Pignatelli P, Carnevale R, Nocella C. Gut-derived low-grade endotoxaemia, atherothrombosis and cardiovascular disease. *Nat Rev Cardiol*. 2023 Jan;20(1):24–37. <https://doi.org/10.1038/s41569-022-00737-2>
- [38] Zheng Z, Mukhametova L, Boffa MB, et al. Assays to quantify fibrinolysis: strengths and limitations. Communication from the International Society on Thrombosis and Haemostasis Scientific and Standardization Committee on fibrinolysis. *J Thromb Haemost*. 2023.
- [39] Zheng Z, Nayak L, Wang W, et al. An ATF6-tPA pathway in hepatocytes contributes to systemic fibrinolysis and is repressed by DACH1. *Blood*. 2019;133(7):743-753.
- [40] Zheng Z, Nakamura K, Gershbaum S, et al. Interacting hepatic PAI-1/tPA gene regulatory pathways influence impaired fibrinolysis severity in obesity. *J Clin Invest*. 2020;130(8):4348-4359.